Paper9528852
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.
Jensen DE and 18 others. Oncogene, 1998. Cited by 619 papers, by iCite.
Cite this record
ConductScience Library. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Papers, record 9528852. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9528852
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics27
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| BRCA1 Protein | Major topic |
| Breast Neoplasms | Major topic |
| Carrier Proteins | Major topic |
| Thiolester Hydrolases | Major topic |
| Tumor Suppressor Proteins | Major topic |
| Ubiquitin Thiolesterase | Major topic |
| Ubiquitin-Protein Ligases | Major topic |
| Amino Acid Sequence | |
| Animals | |
| Base Sequence | |
| Binding Sites | |
| Cell Division | |
| Chromosome Mapping | |
| Chromosomes, Human, Pair 3 | |
| Female | |
| Gene Rearrangement | |
| Homozygote | |
| Humans | |
| Karyotyping | |
| Lung Neoplasms | |
| Mice | |
| Molecular Sequence Data | |
| Recombinant Proteins | |
| Sequence Alignment | |
| Sequence Homology, Amino Acid | |
| Transfection | |
| Zinc Fingers |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA71513 | NCI NIH HHS | United States | R01CA071513 | PubMed and NIH | NIH RePORTER |
| GM30308 | NIGMS NIH HHS | United States | R01GM030308 | PubMed and NIH | NIH RePORTER |
| NCI P50 | NCPDCID CDC HHS | United States | PubMed | PubMed |
Cited by346
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 619 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42943290 | Inhibition of BAP1 Sensitizes Gastric Cancer Cells to 5-Fluorouracil by Promoting BIRC5 Degradation. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42943290 | PubMed |
| 42603824 | Bap1-mediated deubiquitination determines immune tolerance and anti-tumor immunity via modulating eTreg cell differentiation and ferroptosis. | Cell Death Differ | 2026 | https://conductscience.org/library/papers/42603824 | PubMed |
| 42502634 | The Prognostic Significance of BRCA1-Associated Protein 1(BAP1) in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis. | Clin Med Insights Oncol | 2026 | https://conductscience.org/library/papers/42502634 | PubMed |
| 42499709 | Tumor suppressor BAP1 emerges as a key regulator of metabolism and cell death in tumors. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42499709 | PubMed |
| 42319595 | From Ferroptotic Stress to Stemness: TNT-Mediated EMT Plasticity in Cancer Progression. | Stem Cell Rev Rep | 2026 | https://conductscience.org/library/papers/42319595 | PubMed |
| 42211514 | Prognostic value of BAP1 expression in uveal melanoma: a comparative study with histopathological factors in a large Spanish cohort. | Front Oncol | 2026 | https://conductscience.org/library/papers/42211514 | PubMed |
| 42189393 | Essential genetic mutations impair DNA damage repair and modulate tumor immune microenvironment in ccRCC. | MedScience | 2026 | https://conductscience.org/library/papers/42189393 | PubMed |
| 42069682 | BAP1 and USP1 cooperate to regulate FANCD2 stability and cell proliferation in mesothelioma cells. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42069682 | PubMed |
| 41971442 | From biology to therapy: current standards and emerging strategies in pleural mesothelioma. | Front Oncol | 2026 | https://conductscience.org/library/papers/41971442 | PubMed |
| 41938102 | Spatial immune profiling complements genomic sequencing in biliary tract cancer: hypothesis-generating use cases. | ESMO Gastrointest Oncol | 2026 | https://conductscience.org/library/papers/41938102 | PubMed |
| 41751865 | Semi-Quantitative Evaluation of BRCA1 Protein in Breast Tumors Using Anti-BRCA1 Antibodies: Clinical Implications. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41751865 | PubMed |
| 41737289 | Current Therapies and Potential Strategies for Uveal Melanoma. | Drugs Drug Candidates | 2025 | https://conductscience.org/library/papers/41737289 | PubMed |
| 41718807 | BRCA1-Associated Protein 1 (BAP1) in Human Cancer and its Emerging Role as a Novel Potential Therapeutic Target. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/41718807 | PubMed |
| 41647837 | Roles of E3 ubiquitin ligases and deubiquitinating enzymes in renal cell carcinoma. | Front Oncol | 2025 | https://conductscience.org/library/papers/41647837 | PubMed |
| 41613812 | Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art. | Oncol Res | 2026 | https://conductscience.org/library/papers/41613812 | PubMed |
| 41595762 | The Mechanism and Regulation of Disulfidptosis and Its Role in Disease. | Biomedicines | 2026 | https://conductscience.org/library/papers/41595762 | PubMed |
| 41551629 | A case of polydactylous nail changes and BAP1-tumor predisposition syndrome: Implications for earlier detection. | JAAD Case Rep | 2026 | https://conductscience.org/library/papers/41551629 | PubMed |
| 41501212 | BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities. | Oncogene | 2026 | https://conductscience.org/library/papers/41501212 | PubMed |
| 41387680 | Early genetic evolution of driver mutations in uveal melanoma. | Nat Commun | 2025 | https://conductscience.org/library/papers/41387680 | PubMed |
| 41291679 | Restoration of BAP1 activity via base editing suppresses anchorage-independent survival in kidney cancer. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/41291679 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BAP1 | 8314 | Swiss-Prot's references | https://conductscience.org/library/genes/8314 | NCBI Gene |
| BRCA1 | 672 | Swiss-Prot's references | https://conductscience.org/library/genes/672 | NCBI Gene |
| BARD1 | 580 | PubTator's text mining | https://conductscience.org/library/genes/580 | NCBI Gene |
| MAGI1 | 9223 | PubTator's text mining | https://conductscience.org/library/genes/9223 | NCBI Gene |
| UCHL1 | 7345 | PubTator's text mining | https://conductscience.org/library/genes/7345 | NCBI Gene |
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| GENBANK | AF045581 |
Source GENBANK
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9528852
GET https://conductscience.org/api/papers/v1/9528852/cited_by?page=2